Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline?

Ignace Vergote,Isabelle Ray-Coquard,Domenica Lorusso,Ana Oaknin,David Cibula,Toon Van Gorp

Expert opinion on investigational drugs（2023）

引用 0|浏览37

暂无评分

摘要

Therapeutics currently attracting attention include novel immune checkpoint inhibitors, therapeutic vaccinations, antibody-drug conjugates, such as tisotumab vedotin, tyrosine kinase inhibitors targeting HER2, and multitarget synergistic combinations.

查看译文

关键词

Recurrent cervical cancer,advanced metastatic cervical cancer,antibody–drug conjugate,combination therapy,immunotherapy,investigational drugs,tyrosine kinase inhibitor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要